{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:24:27Z","timestamp":1775219067498,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:00:00Z","timestamp":1590278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.afos.2020.05.006","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T08:05:50Z","timestamp":1592899550000},"page":"39-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5790-3567","authenticated-orcid":false,"given":"Md","family":"Azharuddin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9202-0524","authenticated-orcid":false,"given":"Mohammad","family":"Adil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4933-2893","authenticated-orcid":false,"given":"Rashid Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9616-0911","authenticated-orcid":false,"given":"Pinaki","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-0675","authenticated-orcid":false,"given":"Prem","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-6626","authenticated-orcid":false,"given":"Manju","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.afos.2020.05.006_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jbspin.2009.04.009","article-title":"Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis","volume":"77","author":"Fardellone","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.afos.2020.05.006_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF01623184","article-title":"Hip fractures in the elderly: a world-wide projection","volume":"2","author":"Cooper","year":"1992","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1359\/jbmr.2005.20.5.886","article-title":"How many women have osteoporosis? JBMR anniversary classic. JBMR, volume 7, number 9, 1992","volume":"20","author":"Melton","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2020.05.006_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2020.05.006_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-013-9724-8","article-title":"Health technology assessment in osteoporosis","volume":"93","author":"Hiligsmann","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2020.05.006_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"24","author":"Kanis","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6904-10-5","article-title":"EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage","volume":"10","author":"P\u00fcntmann","year":"2010","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.afos.2020.05.006_bib8","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.socscimed.2007.06.009","article-title":"Cost-effectiveness analysis and formulary decision making in England: findings from research","volume":"65","author":"Williams","year":"2007","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.afos.2020.05.006_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.afos.2020.05.006_bib10","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.afos.2020.05.006_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1017\/S0266462305050324","article-title":"Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria","volume":"21","author":"Evers","year":"2005","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.afos.2020.05.006_bib12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated health economic evaluation reporting standards (CHEERS)--explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.afos.2020.05.006_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00005650-200301000-00007","article-title":"Development and validation of a grading system for the quality of cost-effectiveness studies","volume":"41","author":"Chiou","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.afos.2020.05.006_bib14","first-page":"53","article-title":"Examining the value and quality of health economic analyses: implications of utilizing the QHES","volume":"9","author":"Ofman","year":"2003","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.afos.2020.05.006_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40273-014-0231-1","article-title":"A\u00a0systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis","volume":"33","author":"Hiligsmann","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.afos.2020.05.006_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.radonc.2017.08.034","article-title":"A\u00a0systematic review of health economic evaluation in adjuvant breast radiotherapy: quality counted by numbers","volume":"125","author":"Monten","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.afos.2020.05.006_bib17","series-title":"2018 international congress. Movement disorders; monday, 2018 Oct 8","first-page":"S836","article-title":"Assessing the quality of economic evaluation of treatment options for Parkinson\u2019s disease using the quality of health economic studies (QHES) Scale","author":"Azharuddin","year":"2018"},{"key":"10.1016\/j.afos.2020.05.006_bib18","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1177\/0363546514544684","article-title":"Cost-effectiveness analyses in orthopaedic sports medicine: a systematic review","volume":"43","author":"Nwachukwu","year":"2015","journal-title":"Am J Sports Med"},{"key":"10.1016\/j.afos.2020.05.006_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/s12913-017-2374-1","article-title":"Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews","volume":"17","author":"Azar","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.afos.2020.05.006_bib20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.afos.2020.05.006_bib21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40273-015-0266-y","article-title":"Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes","volume":"33","author":"Geng","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.afos.2020.05.006_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/oemed-2012-100668","article-title":"Worksite mental health interventions: a systematic review of economic evaluations","volume":"69","author":"Hamberg-van Reenen","year":"2012","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.afos.2020.05.006_bib23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40273-016-0397-9","article-title":"A\u00a0systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions","volume":"34","author":"Plumpton","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.afos.2020.05.006_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1524-4733.2007.00255.x","article-title":"Reliability of two instruments for critical assessment of economic evaluations","volume":"11","author":"Au","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.afos.2020.05.006_bib25","series-title":"Best practices for conducting economic evaluations in health care: a systematic review of quality assessment tools","author":"Walker","year":"2012"},{"key":"10.1016\/j.afos.2020.05.006_bib26","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1398-9995.2008.01888.x","article-title":"Health economics of asthma: assessing the value of asthma interventions","volume":"63","author":"Campbell","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.afos.2020.05.006_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.radonc.2017.11.005","article-title":"Adjuvant breast radiotherapy: how to trade-off cost and effectiveness?","volume":"126","author":"Monten","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.afos.2020.05.006_bib28","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.19082\/3434","article-title":"Cost-effectiveness of zoledronic acid to prevent and treat postmenopausal osteoporosis in comparison with routine medical treatment","volume":"8","author":"Golmohamdi","year":"2016","journal-title":"Electron Physician"},{"key":"10.1016\/j.afos.2020.05.006_bib29","first-page":"53","article-title":"The cost effectiveness of zoledronic acid 5\u2009mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and The Netherlands","volume":"14","author":"Akehurst","year":"2011","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.afos.2020.05.006_bib30","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01622200","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group","volume":"4","author":"Kanis","year":"1994","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","article-title":"Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bone.2009.08.052","article-title":"Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years","volume":"46","author":"Hiligsmann","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.afos.2020.05.006_bib33","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00198-016-3772-7","article-title":"Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA","volume":"28","author":"Mori","year":"2017","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"10.1016\/j.afos.2020.05.006_bib34","first-page":"3","article-title":"Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada","volume":"15","author":"Chau","year":"2012","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.afos.2020.05.006_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CEOR.S78349","article-title":"Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain","volume":"7","author":"Darb\u00e0","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.afos.2020.05.006_bib36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/11539980-000000000-00000","article-title":"Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium","volume":"29","author":"Hiligsmann","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.afos.2020.05.006_bib37","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","article-title":"Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis","volume":"22","author":"J\u00f6nsson","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","article-title":"Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US","volume":"11","author":"Parthan","year":"2013","journal-title":"Appl Health Econ Health Pol"},{"key":"10.1016\/j.afos.2020.05.006_bib39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/CEOR.S42755","article-title":"Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain","volume":"5","author":"Darb\u00e0","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.afos.2020.05.006_bib40","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/jbmr.1819","article-title":"Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women","volume":"28","author":"Hiligsmann","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2020.05.006_bib41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00198-013-2521-4","article-title":"Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm","volume":"25","author":"Kim","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF03324794","article-title":"Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis","volume":"22","author":"Berto","year":"2010","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.afos.2020.05.006_bib43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1524-4733.2009.00666.x","article-title":"The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis","volume":"13","author":"Thompson","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.afos.2020.05.006_bib44","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00198-017-3973-8","article-title":"Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan","volume":"28","author":"Moriwaki","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1471-2474-13-213","article-title":"The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden","volume":"13","author":"Murphy","year":"2012","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.afos.2020.05.006_bib46","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.clinthera.2017.05.348","article-title":"A\u00a0model for assessing the clinical and economic benefits of bone-forming agents for reducing fractures in postmenopausal women at high, near-term risk of osteoporotic fracture","volume":"39","author":"O\u2019Hanlon","year":"2017","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.afos.2020.05.006_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022585","article-title":"Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA","volume":"8","author":"Ito","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.afos.2020.05.006_bib48","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00198-018-04821-7","article-title":"Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France","volume":"30","author":"Hiligsmann","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1185\/030079908X260998","article-title":"Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands","volume":"24","author":"Jansen","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.afos.2020.05.006_bib50","first-page":"605","article-title":"Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations","volume":"14","author":"Tosteson","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.afos.2020.05.006_bib51","first-page":"499","article-title":"Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective","volume":"11","author":"Wasserfallen","year":"2008","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.afos.2020.05.006_bib52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40273-016-0448-2","article-title":"Systematic review and quality appraisal of cost-effectiveness analyses of pharmacologic maintenance treatment for chronic obstructive pulmonary disease: methodological considerations and recommendations","volume":"35","author":"van der Schans","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.afos.2020.05.006_bib53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2007.10.019","article-title":"The cost-effectiveness of alendronate in the management of osteoporosis","volume":"42","author":"Kanis","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.afos.2020.05.006_bib55","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.bone.2010.07.024","article-title":"Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer","volume":"47","author":"Iverg\u00e5rd","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.afos.2020.05.006_bib56","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/erp.12.8","article-title":"The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis","volume":"12","author":"Hiligsmann","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.afos.2020.05.006_bib57","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1007\/s00198-011-1668-0","article-title":"Partial adherence: a new perspective on health economic assessment in osteoporosis","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib58","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1517\/14656560903140533","article-title":"Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence","volume":"10","author":"Rabenda","year":"2009","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.afos.2020.05.006_bib59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00223-009-9329-4","article-title":"Potential clinical and economic impact of nonadherence with osteoporosis medications","volume":"86","author":"Hiligsmann","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2020.05.006_bib60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jbspin.2012.01.001","article-title":"Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX\u2122 thresholds for decision","volume":"80","author":"Alzahouri","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.afos.2020.05.006_bib61","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00198-010-1291-5","article-title":"Cost-effectiveness of bazedoxifene incorporating the FRAX\u00ae algorithm in a European perspective","volume":"22","author":"Borgstr\u00f6m","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00198-005-1943-z","article-title":"Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature","volume":"17","author":"Fleurence","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00198-006-0257-0","article-title":"Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model","volume":"18","author":"Zethraeus","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00198-013-2551-y","article-title":"A\u00a0systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures","volume":"25","author":"Si","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib65","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.38737.607558.80","article-title":"Bias in published cost effectiveness studies: systematic review","volume":"332","author":"Bell","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.afos.2020.05.006_bib66","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11530530-000000000-00000","article-title":"Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis","volume":"28","author":"Fleurence","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.afos.2020.05.006_bib67","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1186\/ar4465","article-title":"Patients\u2019 preferences for osteoporosis drug treatment: a discrete-choice experiment","volume":"16","author":"Hiligsmann","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.afos.2020.05.006_bib68","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bone.2007.09.059","article-title":"Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK\u2014results based on the Women\u2019s Health Initiative randomised controlled trial","volume":"42","author":"Lekander","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.afos.2020.05.006_bib69","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00774-007-0794-4","article-title":"The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis","volume":"26","author":"Ding","year":"2008","journal-title":"J\u00a0Bone Miner Metabol"},{"key":"10.1016\/j.afos.2020.05.006_bib70","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00198-007-0504-z","article-title":"Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis","volume":"19","author":"Grima","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1524-4733.2008.00497.x","article-title":"Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis","volume":"12","author":"Hiligsmann","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.afos.2020.05.006_bib72","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjmed.2008.07.026","article-title":"The cost-effectiveness of hormone therapy in younger and older postmenopausal women","volume":"122","author":"Salpeter","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.afos.2020.05.006_bib73","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1089\/jwh.2008.1246","article-title":"Cost-effectiveness of hormone therapy in the United States","volume":"18","author":"Lekander","year":"2009","journal-title":"J\u00a0Womens Health"},{"key":"10.1016\/j.afos.2020.05.006_bib74","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-009-0971-5","article-title":"The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis","volume":"21","author":"Borgstr\u00f6m","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib75","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00198-009-0989-8","article-title":"The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX\u00ae","volume":"21","author":"Borgstr\u00f6m","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib76","first-page":"381","article-title":"Cost effectiveness of teriparatide and PTH (1-84) in the treatment of postmenopausal osteoporosis","volume":"13","author":"Borgstr\u00f6m","year":"2010","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.afos.2020.05.006_bib77","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00198-009-0924-z","article-title":"Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women","volume":"21","author":"Hiligsmann","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib78","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.03.009","article-title":"Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women","volume":"47","author":"Hiligsmann","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.afos.2020.05.006_bib79","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bone.2009.12.006","article-title":"Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age","volume":"46","author":"Seeman","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.afos.2020.05.006_bib80","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.bone.2010.05.020","article-title":"FRAX\u00ae and its applications in health economics\u2014cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example","volume":"47","author":"Str\u00f6m","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.afos.2020.05.006_bib81","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/j.1532-5415.2011.03571.x","article-title":"Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy","volume":"59","author":"Pham","year":"2011","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.afos.2020.05.006_bib82","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s00198-011-1869-6","article-title":"Cost-effective intervention thresholds against osteoporotic fractures based on FRAX\u00ae in Switzerland","volume":"23","author":"Lippuner","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib83","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jbmr.1755","article-title":"Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan","volume":"28","author":"Moriwaki","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2020.05.006_bib84","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00198-012-2115-6","article-title":"Intervention thresholds for denosumab in the UK using a FRAX\u00ae-based cost-effectiveness analysis","volume":"24","author":"Str\u00f6m","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12962-016-0060-5","article-title":"What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia","volume":"14","author":"Karnon","year":"2016","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.afos.2020.05.006_bib86","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00198-017-3940-4","article-title":"Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan","volume":"28","author":"Mori","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2020.05.006_bib87","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11657-018-0509-6","article-title":"Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate","volume":"13","author":"Yoshizawa","year":"2018","journal-title":"Arch Osteoporos"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525520300534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525520300534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:35:03Z","timestamp":1762500903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405525520300534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2405525520300534"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2020.05.006","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2020.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}